stockrowPraxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) EPS (diluted)
Praxis Precision Medicines, Inc.'s EPS (diluted) for fiscal 2025 was −$13.48, compared with −$10.21 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$12.93. Over the past ten years it has ranged from −$398.94 (fiscal 2019) to −$10.21 (fiscal 2024); the current reading is higher than 88% of that period. Praxis Precision Medicines, Inc. ranks 507th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$13.48 | — |
| FY2024 | −$10.21 | — |
| FY2023 | −$18.69 | — |
| FY2022 | −$69.57 | — |
| FY2021 | −$59.07 | — |
| FY2020 | −$117.84 | — |
| FY2019 | −$398.94 | — |
| FY2018 | −$306.49 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$2.87 | — |
| Mar 2026 | −$3.20 | — |
| Dec 2025 | −$3.50 | — |
| Sep 2025 | −$3.36 | — |
| 23 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $7.37 |
| CORT Corcept Therapeutics Incorporated compare | $1.29 |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$2.25 |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −$2.89 |
| AXSM Axsome Therapeutics, Inc. compare | −$3.06 |
| SYRE Spyre Therapeutics, Inc. compare | −$3.07 |
| CYTK Cytokinetics, Incorporated compare | −$6.04 |
| ABVX Abivax SA Sponsored ADR compare | −$6.06 |
| PRAX Praxis Precision Medicines, Inc. | −$12.93 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item